xCELLcelligence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 985-994

  Martinez Serra, Jordi ^a   Ggutierrez, Antonio ^a   Muñoz Ccapó, Saúl ^a   Nnavarro Palou, María ^a   Rros, Teresa ^a   Aamat, Juan Ccarlos ^a   Lopez, Bernardo ^a   Marcus, Toni F ^a   Fueyo, Laura ^a   Suquia, Angela G ^a   Gines, Jordi ^a   Rrubio, Francisco ^a   Rramos, Rrafael ^a   Besalduch, Joan ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Drug discovery; Leukemia; Lymphoma; Real time cell analysis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; BENDAMUSTINE; CISPLATIN; COLLAGEN; DOXORUBICIN; FAS LIGAND; FIBRONECTIN; GELATIN; GEMCITABINE; LAMININ; OXALIPLATIN; PENICILLIN DERIVATIVE; STREPTOMYCIN; TRABECTEDIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANALYTIC METHOD; ARTICLE; CELL ADHESION; CELL CULTURE; CELL GROWTH; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DRUG MONITORING; EXTRACELLULAR MATRIX; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HUMAN CELL; JURKAT CELL LINE; LEUKEMIA CELL; LYMPHOMA CELL; MICROELECTRODE; SINGLE CELL ANALYSIS; T CELL LEUKEMIA; XCELLIGENCE SYSTEM;

EID: 84902436327     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S62887     Document Type: Article

References (20)

1. Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2012; 11(6): 479-497.
2. Kustermann S, Boess F, Buness A, et al. A label-free, impedance-based real time assay to identify drug-induced toxicities and differentiate cytostatic from cytotoxic effects. Toxicol In Vitro. 2013; 27(5): 1589-1595.
3. Limame R, Wouters A, Pauwels B, et al. Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One. 2012; 7(10): e46536.
4. Obr A, Röselová P, Grebeňová D, Kuželová K. Real-time monitoring of hematopoietic cell interaction with fibronectin fragment: the effect of histone deacetylase inhibitors. Cell Adh Migr. 7(3): 275-282.
5. Hamawy MM, Oliver C, Mergenhagen SE, Siraganian RP. Adherence of rat basophilic leukemia (RBL-2H3) cells to fibronectin-coated surfaces enhances secretion. J Immunol. 1992; 149(2): 615-621.
6. Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003; 9(9): 1158-1165.
7. Mobley JL, Ennis E, Shimizu Y. Differential activation-dependent regulation of integrin function in cultured human T-leukemic cell lines. Blood. 1994; 83(4): 1039-1050.
8. Daker M, Ahmad M, Khoo AS. Quercetin-induced inhibition and synergistic activity with cisplatin-a chemotherapeutic strategy for nasopharyngeal carcinoma cells. Cancer Cell Int. 2012; 12(1): 34.
9. Hanusová V, Králová V, Schröterová L, Trilecová L, Pakostová A, Skálová L. The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF7 cells. Xenobiotica. 2010; 40(10): 681-690.
10. Kumar B, Yadav A, Lang J, Teknos TN, Kumar P. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One. 2012; 7(5): e37601.
11. Yamashita-Kashima Y, Iijima S, Yorozu K, et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res. 2011; 17(15): 5060-5070.
12. Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract. 2012; 2012: 283181.
13. Ivanoff J, Talme T, Sundqvist KG. The role of chemokines and extracellular matrix components in the migration of T lymphocytes into three-dimensional substrata. Immunology. 2005; 114(1): 53-62.
14. Ricard I, Payet MD, Dupuis G. Clustering the adhesion molecules VLA-4 (CD49d/CD29) in Jurkat T cells or VCAM-1 (CD106) in endothelial (ECV 304) cells activates the phosphoinositide pathway and triggers Ca2+ mobilization. Eur J Immunol. 1997; 27(6): 1530-1538.
15. Harima A, Nakaseko C, Yokota A, et al. Fibronectin promotes cell proliferation of human pre-B cell line via its interactions with VLA-4 and VLA-5. Hematology. 2008; 13(4): 236-243.
16. Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002; 115(Pt 20): 3861-3863.
17. Mudry RE, Fortney JE, York T, Hall BM, Gibson LF. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood. 2000; 96(5): 1926-1932.
18. Bradstock KF, Gottlieb DJ. Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Leuk Lymphoma. 1995; 18(1-2): 1-16.
19. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9(9): 665-674.
20. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008; 14(9): 2519-2526.